Abstract: The purpose of this study was to test the hypothesis that skeletal muscle relaxants could inhibit the in vitro metabolism of common comedications opioids buprenorphine, methadone and oxycodone. The compounds [solubility-limited concentration (lM) studied] were as follows: baclofen (1000), carisoprodol (200), its metabolite meprobamate (1000), chlorzoxazone (200), cyclobenzaprine (1000), metaxalone (50), methocarbamol (1000), orphenadrine (1000) and tizanidine (1000). Compounds were first incubated with human liver microsomes AE pre-incubation, screened with pathway-specific cDNA-expressed cytochrome P450s (rCYP), and then IC 50 values determined using either 8-concentration tests for those where the rCYP screen suggested an IC 50 was achievable, or a 3-concentration test with downward extrapolation if screen suggested 50% inhibition was not achievable. These results were then extrapolated to determine an inhibitory potential. Six pathway inhibitor combinations were identified with a moderate inhibitory potential (≥2.0 < 5.0): five with chlorzoxazone, R-EDDP, S-EDDP and noroxycodone production by CYP3A4, and R-and S-EDDP production by CYP2B6; and one for the meprobamate effect on noroxycodone production by CYP3A4. An additional eleven combinations were found with a weak inhibitory potential (≥1.25 < 2.0): five with carisoprodol, two each with methocarbamol and meprobamate, and one each with metaxalone and orphenadrine. This represents the first comprehensive study of the inhibitory effect of this class of drugs and suggests that some of them may produce significant drug-drug interactions with opioids that are frequent comedications with skeletal muscle relaxants.
The opioid epidemic continues. According to the latest report from the Centers for Disease Control and Prevention, 60.9% (n = 2864) of all overdoses in 2014 involved an opioid [1] . While the opioids involved have shifted to an increasing contribution by heroin and fentanyl, the synthetic opioids still play a large role in this epidemic [1, 2] . Most of the synthetic opioids are cytochrome P450 (CYP450) metabolites and as such may be subject to drug-drug interactions (DDI) [3, 4] . While opioids are dangerous drugs in their own right, a DDI that inhibits opioid metabolism that deactivates the opioid (e.g. oxycodone to noroxycodone) could increase parent drug concentration from tolerable to toxic. Alternatively, inhibition of a pathway to an active metabolite (e.g. oxycodone to oxymorphone) may decrease the efficacy of the drug. We have therefore undertaken studies on the in vitro inhibition of the metabolism of the opioids [5, 6] . Our studies have focused on opioids for which we have validated quantitative methods buprenorphine [7] , methadone [8] and oxycodone [9] . The primary routes of metabolism for these opioids are shown in fig. 1 . The primary metabolites were also included in our validated methods.
Skeletal muscle relaxants are commonly coprescribed with opioids for the treatment of back pain [10, 11] . With the exception of a single study on orphenadrine [12] , we could not locate any other studies that have evaluated the ability of skeletal muscle relaxants to impact CYP450 metabolism.
We have therefore utilized methods optimized previously to study the in vitro inhibition of buprenorphine [6] , methadone and oxycodone metabolism in human liver microsomes (HLM) and recombinant DNA-expressed CYP450s (rCYP). These studies allow us to investigate the impact of potential interactants with CYP2B6, 2D6, 2C8, 2C18 and 3A4.
Materials and Methods
Insect cell rCYPs (Supersomes) 2B6, 2D6, 2C8, 2C18 and 3A4 with co-expressed NADPH CYP reductase (2B6 and 3A4 also had coexpressed cytochrome b 5 ) and HLM (150 donors, mixed gender) were purchased from Gentest (part of Corning Life Sciences, Tewsbury, MA, USA). Outdated human plasma was obtained from the University of Utah blood bank. Buprenorphine, norbuprenorphine, oxycodone, noroxycodone, oxymorphone, racemic methadone and racemic EDDP perchlorate, and their deuterated internal standards for analyses were purchased from Cerilliant Corp (Round Rock, TX, USA). Baclofen, carisoprodol, cyclobenzaprine HCl, and methocarbamol, were purchased from Toronto Research Chemicals (Toronto, Canada). Tizanidine HCl was purchased from Alfa-Aesar (Tewksbury, MA, USA). Buprenorphine HCl was purchased from Refined Technologies, Inc. (Woodlands, TX, USA). Chlorzoxazone, meprobamate, metaxalone, methadone HCl, orphenadrine citrate, oxycodone HCl and other chemicals were purchased from Sigma-Aldrich Chemical Corp (St. Louis, MO, USA). Solvents were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Water was drawn from a Milli-Q filter apparatus (Millipore Corp, Billerica, MA, USA).
Incubations. Incubations with HLM and rCYPs were conducted under conditions optimized to prevent greater than 10% substrate loss and linear product formation as previously described. In brief, final Author for correspondence: David E. Moody, Center for Human Toxicology, University of Utah, 30 S. 2000 E, Rm 105, Salt Lake City, UT 84112, USA (e-mail david.moody@utah.edu). volumes were 0.2 mL, and substrate concentrations were 20 lM. Protein (HLM or rCYP) and buffer were added first regardless of preincubation. When no pre-incubation was performed, substrate and inhibitor were then added and the reaction initiated by adding an NADPH-generating system (NADPH-GS). When pre-incubation was performed, inhibitor followed by NADPH-GS was added, and after the 15-min. pre-incubation substrate was added. Incubations were conducted in a shaking water bath at 37°C and were terminated by addition of 0.1 mL of ice-cold methanol and transfer to an ice bath. Once a set of incubations was completed, samples were stored at À70°C until the day of analysis.
Sample preparation and liquid chromatography-electrosprayionization-tandem mass spectrometry (LC-MS/MS). Buprenorphine and norbuprenorphine were determined using deuterated internal standards with pH-adjusted plasma by liquid-liquid extraction with nbutyl chloride:acetonitrile (4:1) and monitoring of buprenorphine, d 4 -buprenorphine, norbuprenorphine and d 3 -norbuprenorphine by the respective transitions of m/z 468 to 396, 472 to 400, 414 to 414 and 417 to 417 [7] . Enantiomer-specific methadone and EDDP were determined using liquid-liquid extraction with methyl t-butyl ether and monitoring of methadone, d 3 -methadone, EDDP and d 3 -EDDP by the respective transitions of m/z 310 to 265, 313 to 268, 278 to 234 and 281 to 234. Separation of the R-and S-enantiomers was achieved using a Chiral-AGP column [8] . Oxycodone and metabolite analyses were performed using liquid-liquid extraction with n-butyl chloride: acetonitrile (4:1) and monitoring oxycodone, oxycodone-d 6 , noroxycodone, noroxycodone-d 3 , oxymorphone and oxymorphone-d 3 by the respective transitions of m/z 316 to 298, 322 to 304, 302 to 284, 305 to 287, 302 to 284 and 305 to 287 with chromatographic separation of noroxycodone and oxymorphone as previously described [9] .
Calibrators and quality control samples (QCs) were prepared in human plasma. The use of plasma calibrators for accurate and precise quantitation in HLM was demonstrated during method validation [8, 9, 13] . Calibrators were run at the beginning and end of each batch; QCs were run right before and after analysed samples. QCs were run at low, medium and high concentrations at N ≥ 2 per concentration.
Data analyses/statistics. Inhibitors were incubated with rCYPs at eight different concentrations. Per cent of control activity was plotted versus log concentration and the IC 50 value determined using GraphPad Prism (version 5.0f) software (La Jolla, CA, USA) with one-site-fit LogIC50 nonlinear regression. When a full IC 50 curve was not an option (inhibition was not, or only slightly below, 50%), we attempted to provide estimates of an IC 50 by extrapolation. Three concentrations were tested, one at the maximum and two slightly lower. Plots of percent of control activity versus log concentration were analysed using log-linear regression and extrapolated to the 50% line. Plots were acceptable if R 2 > 0.7. For the comparison of carisoprodol, meprobamate and carisoprodol plus meprobamate, oneway ANOVA was performed with the Tukey's post hoc test also using GraphPad Prism software.
Extrapolations. Inhibitory potential was estimated using equation (1) [14] :
where AUC is the area under the curve for normal (n), inhibitor plasma concentration (i) or three times the inhibitor concentration (3i), and K i is the inhibition constant. K i was estimated from the IC 50 using equation (2) [15] :
Results

Limits on concentrations of inhibitors studied.
It is important to avoid organic solvents in excess of 1.0% in incubations. Aqueous stock solutions are therefore preferred. As the hydrophilicity of the muscle relaxants studied varied extensively, there were corresponding limits to the upper concentration that could be studied; 1000 lM was selected as the highest concentration to study when it was achievable ( fig. 2 ).
Effect in HLM incubated AE pre-incubations.
Muscle relaxants were initially incubated with HLM at three concentrations with and without a 15-min. pre-incubation. This provided preliminary information on inhibitory effect and evidence for time-dependent inhibition (TDI) ( fig. 3 ). Inhibitions that exceeded 50% under these conditions included the following: chlorzoxazone with noroxycodone formation; cyclobenzaprine with all pathways; meprobamate with noroxycodone, R-EDDP and S-EDDP formation; orphenadrine with all but norbuprenorphine formation; and tizanidine with oxymorphone formation. Only tizanidine with methadone was suggestive of TDI, but at such high concentrations that follow-up experiments were impractical ( fig. 3 ).
Effect in rCYPs for specific pathways. Muscle relaxants were then studied with specific pathways and their respective rCYPs ( fig. 4) 
Discussion
The most common reason people go to medical service providers is for pain, with lower back pain being one of the five top reasons. Three skeletal muscle relaxants, metaxalone, carisoprodol and cyclobenzaprine make up 45% of the prescriptions for lower back pain. Some pharmacodynamic DDIs have been noted with skeletal muscle relaxants that primarily involve additive CNS depression with other CNS depressants [10, 11] . The only study we could find on potential for pharmacokinetic DDIs was a study on orphenadrine inhibition of CYP450 activities in HLM and rCYPs. Under competitive inhibition conditions, they observed inhibition of marker substrates as CYP2D6 >> 2B6 > 1A2, 2C19 > 2A6, 3A4 > 2C9. Our studies with orphenadrine can be summarized as CYP2D6 >> 3A4 (methadone) > 3A4 (oxycodone) > 2C18 > 2B6 > 2C8 > 3A4 (buprenorphine). The relative effects on CYP2D6 and 2B6 are in agreement. The disparity of the CYP3A4 IC 50 values is reflective of the plasticity of its large binding site. Six of the muscle relaxants were studied up to the maximum concentration of 1000 lM. Aqueous solubility limited the study of carisoprodol and chlorzoxazone up to 200 lM, while metaxalone could only be studied up to 50 lM. Under these conditions, baclofen and methocarbamol were essentially noninhibitory. Tizanidine only inhibited one pathway, the CYP2D6 metabolism of oxycodone, but that was fairly strong inhibition with an IC 50 of 2.4 lM. The remaining compounds inhibited multiple pathways; cyclobenzaprine inhibited all of them. To test whether these might have some clinical significance, we calculated inhibition potentials. The U.S. Food and Drug Administration has recommended inhibitory potentials for in vivo DDIs of ≥5 as strong, ≥2 < 5 as moderate and ≥1.25 < 2 as weak inhibitors [16] . These were applied to our in vitro data. For AUC i /AUC n , only chlorzoxazone had potentials ≥2 < 5. These moderate inhibitions occurred with metabolism of R-and S-methadone by CYP3A4 and 2B6. In addition, the potential impact of carisoprodol, chlorzoxazone and meprobamate on oxycodone metabolism by CYP3A4 was ≥1.25 < 2 (table 2) . AUC 3i /AUC n was also evaluated. Under these circumstances, the inhibitory potential of oxycodone metabolism by CYP3A4 with chlorzoxazone and meprobamate was also ≥2 < 5. Eleven pathways demonstrated weak inhibition (≥1.25 < 2), oxycodone by CYP3A4 with carisoprodol, metaxalone and methocarbamol; oxycodone by CYP2D6 with carisoprodol and orphenadrine; R-and S-methadone by CYP3A4 with meprobamate; S-methadone by CYP3A4 with carisoprodol and meprobamate; and buprenorphine by CYP3A4 with methocarbamol and by CYP2C8 with carisoprodol (table 2) .
The use of AUC 3i /AUC n is not unreasonable. The pharmacokinetics of several of these drugs is subject to variation based on individual differences, pharmacogenetics, disease and diet. The C max values used for [I] are averages of several subjects (N = 5-24, see table 2 for specifics), so some subjects had higher concentrations. In one pharmacokinetic study of these drugs that provided ranges, those five subjects receiving tablet and solution formulations of orphenadrine had respective C max ranges of 115-213 and 107-196 ng/mL [17] . Steady-state plasma concentrations of cyclobenzaprine are twice as high in elderly and those with mild hepatic insufficiency than healthy younger populations [18] . In contrast, elderly subjects had lower C max values for baclofen [19] . The C max for metaxalone was significantly different if taken in the fasted versus with a high-fat meal (1816 versus 3510 ng/mL) in eight American subjects [20] . Carisoprodol conversion to meprobamate is performed by CYP2C19, thus in poor metabolizers, the ratio of these two active compounds is significantly changed [21] . Most skeletal muscle relaxants are CYP450 metabolites; however, the involvement of specific CYPs has only been determined for a few. Whether these non-phenotyped drugs may also be subject to genetic polymorphisms is not known.
This study presents the most comprehensive investigation of the inhibitory potential of a class of drugs, the skeletal muscle relaxants, using a set of substrates that are commonly coprescribed. Six pathway inhibitor combinations were identified with an inhibitory potential ≥2.0 < 5 (five with chlorzoxazone and one with meprobamate). An additional eleven combinations were found with a weak inhibitory potential ≥1.25 < 2 (five with carisoprodol, two with methocarbamol and meprobamate and one each with metaxalone and orphenadrine). Further clinical studies are merited to see whether these are significant in human subjects. While relatively low doses of opioids would be needed to protect volunteers, the results could still be used to assess whether plasma concentrations in tolerant patients had the potential to rise to toxic concentrations.
